For a child with daily high fever, arthritis, arthralgia, salmon-colored rash, and elevated ESR and CRP, should treatment begin with ibuprofen (non‑steroidal anti‑inflammatory drug) or methotrexate?

Treatment for Suspected Systemic Juvenile Idiopathic Arthritis (sJIA)

This child requires immediate initiation of methotrexate (B) as disease-modifying therapy, with NSAIDs like ibuprofen (A) serving only as adjunctive symptomatic treatment—NSAIDs alone are inadequate for this presentation.

Clinical Recognition

The presentation of daily high fever, arthritis/arthralgia, salmon-colored rash, and elevated inflammatory markers (ESR/CRP) is classic for systemic juvenile idiopathic arthritis (sJIA), now recognized as Still's disease 1. This is a serious condition requiring aggressive disease-modifying treatment to prevent permanent joint damage and preserve quality of life.

Why Methotrexate is the Primary Answer

Methotrexate is the anchor drug and first-choice DMARD for children with active polyarthritis in JIA 2, 3, 2. The 2019 ACR/Arthritis Foundation guidelines explicitly state that:

• Initial therapy with DMARD is recommended over NSAID monotherapy for children with JIA and active polyarthritis 3
• Methotrexate is conditionally recommended as the preferred DMARD over alternatives like leflunomide or sulfasalazine 2, 3
• Early initiation of DMARD therapy is critical for optimal disease outcomes 3

The guidelines emphasize that while methotrexate has moderate quality evidence supporting it, the greater volume of effectiveness data and superior safety profile compared to alternatives make it the clear first choice 3.

Optimal Methotrexate Administration

• Subcutaneous methotrexate is conditionally recommended over oral due to better bioavailability, particularly at higher doses 2, 3
• Typical dosing follows weight-based protocols established in pediatric rheumatology 4
• An adequate trial is considered 3 months, though therapy adjustments may occur at 6-8 weeks if minimal response 3

The Limited Role of NSAIDs (Ibuprofen)

NSAIDs are conditionally recommended only as adjunct therapy, not primary treatment 2, 3. The guidelines are explicit that:

• NSAIDs are appropriate for symptom management only, particularly during initiation or escalation of DMARD therapy 2, 3
• NSAIDs are not appropriate as monotherapy for chronic, persistent synovitis 2, 3
• The recommendation for NSAIDs is conditional based on very low quality evidence 2, 3

While ibuprofen and other NSAIDs are effective for fever reduction and pain control 5, 6, they do not modify disease progression or prevent joint damage in JIA. Using NSAIDs alone in this presentation would be inadequate and potentially harmful by delaying definitive therapy.

Treatment Algorithm

1. Immediate: Start methotrexate as primary disease-modifying therapy

   • Preferably subcutaneous route
   • Consider bridging with short-course oral glucocorticoids for rapid symptom control 3

2. Adjunctive: Add ibuprofen (or another NSAID) for symptomatic relief

   • Use minimum effective dose for shortest duration 7
   • Monitor for gastrointestinal, renal, and cardiovascular risks 7

3. Monitoring: Assess disease activity at 1-3 month intervals

   • Target: clinically inactive disease or remission 1
   • If inadequate response after adequate methotrexate trial, escalate to biologic therapy 3

Critical Pitfalls to Avoid

• Do not use NSAIDs as monotherapy in a child with suspected sJIA—this delays disease-modifying treatment and risks permanent joint damage
• Do not wait for "NSAID failure" before starting methotrexate in a child with this severe presentation
• Ensure proper exclusion of infection and malignancy before initiating immunosuppressive therapy
• Monitor for methotrexate toxicity including hepatotoxicity, bone marrow suppression, and gastrointestinal effects 4
• Consider folate supplementation to reduce methotrexate adverse effects 8

Special Considerations for Systemic Features

For children with prominent systemic features (high fever, rash) characteristic of sJIA/Still's disease, the 2024 EULAR/PReS recommendations suggest that early use of IL-1 or IL-6 inhibitors with short-duration glucocorticoids may be optimal 1. However, methotrexate remains the standard first-line DMARD when biologic therapy is not immediately available or appropriate.

The answer is B (Methotrexate), with A (Ibuprofen) serving only as adjunctive symptomatic therapy.